Literature DB >> 10514236

Motor unit number estimate-based rates of progression of ALS predict patient survival.

C Armon1, M E Brandstater.   

Abstract

We have examined, as predictors of survival in patients with amyotrophic lateral sclerosis (ALS), linear estimates of rates of disease progression (LEP), based on motor unit number estimates (MUNE). Motor unit number estimates of thenar, hypothenar, and extensor digitorum brevis muscles (according to the manual method of McComas), isometric grip and foot dorsiflexion (FD) strength, and forced vital capacity (FVC) were available in 34 patients. Linear estimates of rates of disease progression were derived. Probability of survival was calculated using the Kaplan-Meier method. Motor unit number estimates, LEP based on MUNE, and demographic characteristics were tested as risk factors within the Cox Proportional Hazards Model, using regression techniques. Individually, all MUNE-based LEP were highly significant (P < 0.00005); bulbar onset attained modest significance (P = 0.044). Secondary analysis showed MUNE-based LEP were more significant than regionally concordant function-based LEP. Linear estimates of rates of disease progression based on MUNE may thus predict survival of patients with ALS better than LEP based on function. Copyright 1999 John Wiley & Sons, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10514236     DOI: 10.1002/(sici)1097-4598(199911)22:11<1571::aid-mus13>3.0.co;2-0

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  9 in total

Review 1.  Measures and markers in amyotrophic lateral sclerosis.

Authors:  Merit Cudkowicz; Muhammad Qureshi; Jeremy Shefner
Journal:  NeuroRx       Date:  2004-04

Review 2.  Use of biomarkers in ALS drug development and clinical trials.

Authors:  Nadine Bakkar; Ashley Boehringer; Robert Bowser
Journal:  Brain Res       Date:  2014-10-24       Impact factor: 3.252

3.  Identification of B6SJL mSOD1(G93A) mouse subgroups with different disease progression rates.

Authors:  Melissa M Haulcomb; Nichole A Mesnard-Hoaglin; Richard J Batka; Rena M Meadows; Whitney M Miller; Kathryn P Mcmillan; Todd J Brown; Virginia M Sanders; Kathryn J Jones
Journal:  J Comp Neurol       Date:  2015-06-22       Impact factor: 3.215

4.  Motor unit number estimation in evaluating disease progression in patients with amyotrophic lateral sclerosis.

Authors:  Suk-Won Ahn; Su-Hyun Kim; Dong-Hoon Oh; Sung-Min Kim; Kyung Seok Park; Yoon-Ho Hong; Oh-Sang Kwon; Jung-Joon Sung; Kwang-Woo Lee
Journal:  J Korean Med Sci       Date:  2010-08-14       Impact factor: 2.153

Review 5.  Prognostic factors in ALS: A critical review.

Authors:  Adriano Chiò; Giancarlo Logroscino; Orla Hardiman; Robert Swingler; Douglas Mitchell; Ettore Beghi; Bryan G Traynor
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

Review 6.  Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.

Authors:  Gary Ginsberg; Serena Lowe
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 7.  Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations.

Authors:  Robert Bowser; Martin R Turner; Jeremy Shefner
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

8.  Multipoint incremental motor unit number estimation versus amyotrophic lateral sclerosis functional rating scale and the medical research council sum score as an outcome measure in amyotrophic lateral sclerosis.

Authors:  Sujit Abajirao Jagtap; Abraham Kuruvilla; Preetha Govind; Muralidharan D Nair; C Sarada; Ravi Prasad Varma
Journal:  Ann Indian Acad Neurol       Date:  2014-07       Impact factor: 1.383

9.  Muscle contractility dysfunction precedes loss of motor unit connectivity in SOD1(G93A) mice.

Authors:  Christopher G Wier; Alexander E Crum; Anthony B Reynolds; Chitra C Iyer; Deepti Chugh; Marilly S Palettas; Patrick L Heilman; David M Kline; W David Arnold; Stephen J Kolb
Journal:  Muscle Nerve       Date:  2018-12-21       Impact factor: 3.217

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.